EU reviews J&J COVID-19 vaccine for blood clots, expands AstraZeneca probe

By , , and
1 minute read
Register now for FREE unlimited access to Reuters.com
  • EMA says no causal link yet of blood clots to either vaccine
  • Four cases of blood clots in recipients of J&J shots
  • J&J says working with regulators to assess data on its vaccine
  • Probe of AstraZeneca vaccine and blood clots already ongoing

April 9 (Reuters) - Europe's drug regulator said on Friday it had started reviewing reports of a bleeding condition in people who had received AstraZeneca's (AZN.L) COVID-19 vaccine and was also looking into Johnson & Johnson's (JNJ.N) shot over blood clots.

Four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with J&J's vaccine from its Janssen unit, the European Medicines Agency said, adding five cases of capillary leak syndrome in people who received AstraZeneca's vaccine were reported.

Register now for FREE unlimited access to Reuters.com
Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.